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Abstract  Pulmonary  adenocarcinomas  are  still  in  the  process  of  achieving  morphological,
immunohistochemical  and  genetic  standardization.  The  ATS/ERS/IASLC  proposed  classiﬁcation
for lung  adenocarcinomas  supports  the  value  of  the  identiﬁcation  of  histological  patterns,
speciﬁcally  in  biopsies.
Thirty  pulmonary  adenocarcinomas  were  subjected  to  immunohistochemical  study  (CK7,  CK5,
6, 18,  CK20,  TTF1,  CD56,  HER2,  EGFR  and  Ki-67),  FISH  and  PCR  followed  by  sequencing  and
fragment  analysis  for  EGFR,  HER2  and  KRAS.
Solid  pattern  showed  lower  TTF1  and  higher  Ki-67  expression.  TTF1  expression  was  higher
in non-mucinous  lepidic  and  micropapillary  patterns  when  compared  to  acinar  and  solid  and
acinar, solid  and  mucinous  respectively.  Higher  Ki67  expression  was  present  in  lepidic  and  solid
patterns compared  to  mucinous.  EGFR  membranous  staining  had  increasing  expression  from
non-mucinous  lepidic/BA  pattern  to  solid  pattern  and  micropapillary  until  acinar  pattern.  EGFR
mutations,  mainly  in  exon  19,  were  more  frequent  in  females,  together  with  non-smoking  status,
while KRAS  exon  2  mutations  were  statistically  more  frequent  in  males,  especially  in  solid
pattern. FISH  EGFR  copy  was  correlated  gross,  with  mutations.  HER2  copy  number  was  raised
in female  tumours  without  mutations,  in  all  cases.  Although  EGFR  and  KRAS  mutations  are
generally considered  mutually  exclusive,  in  rare  cases  they  can  coexist  as  it  happened  in  one  of
this series,  and  was  represented  in  acinar  pattern  with  rates  of  42.9%  and  17.9%,  respectively.
EGFR mutations  were  more  frequent  in  lepidic/BA  and  acinar  patterns.  Some  cases  showedd  between  the  adenocarcinoma  patterns  reinforce  the  need  to
rns  present,  with  implications  in  diagnosis  and  in  pathogenic  under-
tational  status  can  be  determined  in  biopsies  representing  bronchialdifferent EGFR  mutations.
The  differences  identiﬁe
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pulmonary  carcinomas  because  when  a  mutation  is  present  it  is  generally  present  in  all  the
histological  patterns.
© 2014  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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bronchial-pulmonary  adenocarcinomas  mainly  to  validatentroduction
here  are  1.3  million  deaths  from  lung  cancer  annually
orldwide  and  it  is  the  leading  cause  of  cancer-
elated  mortality  in  USA,  Japan  and  Western-countries.1--4
ronchial-pulmonary  carcinomas  were  classiﬁed  as  small
ell  lung  cancer  (SCLC)  and  non-small  cell  lung  can-
er  (NSCLC),  representing  13%  and  85%  of  lung  cancers
espectively.  Squamous  cell  carcinoma  (SQCC)  and  ade-
ocarcinoma  (ADC)  subdivision  become  mandatory  due  to
ersonalized  therapy  and  NSCLC  designation  should  not  be
eported.5,6
Bronchial-pulmonary  adenocarcinomas  are  malignant
pithelial  tumours  with  glandular  differentiation,  and/or
ucin  production,  acinar,  papillary,  micropapillary,  bron-
hioloalveolar  (BA)/lepidic,  or  solid  with  mucin  growth
atterns,  complementing  the  morphological  spectrum  of
ixed-type  adenocarcinoma.  The  incidence  differs  with
ender  and  population,  being  roughly  28%  in  men  and  42%
n  women.  Recently  a  new  classiﬁcation  was  proposed  by
TS/ERS/IASLC.  This  new  classiﬁcation  recognizes  several
atterns  such  as  lepidic  instead  of  BA,  acinar,  papillary,
olid,  and  micropapillary.  It  also  recognizes  mucinous  adeno-
arcinomas  including  the  former  mucinous  BA  carcinoma
nd  colloid  carcinoma.  It  also  highlighted  the  need  for  an
ssertive  diagnosis  specially  in  biopsy  material,  supported
y  immunohistochemical  study,  with  clinical,  prognostic  and
herapeutic  implications.5--8
The  transmembrane  tyrosine  kinase  epidermal  growth
actor  receptor  (EGFR) belonging  to  the  EGFR  family  of
eceptor  tyrosine  kinases  (TKs)  called  the  HER  or  ErbB  fam-
ly  (consisting  of  four  members  --  EGFR  (HER1/ErbB1), HER2
ErbB2),  HER3  (ErbB3)  and  HER4  (ErbB4))9,10 may  be  over-
xpressed  and  this  correlates  with  poor  prognosis,  with
ggressive  disease  and  decreased  survival.3,11--14
KRAS  mutations  are  associated  with  poor  prognosis,
eported  since  1990,  occurring  in  codon  12,  occasion-
lly  at  codon  13  and  rarely  at  codon  61.10,15,16 According
o  the  current  data,  EGFR  and  KRAS  mutations  are
utually  exclusive10,17,18;  the  explanation  is  related  to
RAS-MAPK  pathway  inserts  in  the  downstream  signalling
athway  of  EGF.10 This  mutation  appears  in  30%  of  Cau-
asian  patients  with  lung  cancer  and  10%  of  East  Asian
denocarcinomas.16,18,19 KRAS  mutations  are  more  frequent
n  smokers  and  are  related  to  poor  prognosis.10,16,17 Lung
ancers  with  KRAS  mutations  are  resistant  to  EGFR-TKIs  and
atabe  conﬁrmed  in  his  study  that  none  of  the  lung  cancers
ith  KRAS  mutation  achieved  clinical  response.10,20
Due  to  what  has  been  said,  the  EGFR-MAPK  signal
ransduction  pathway  is  important  to  understand  the  role
f  individual  somatic  changes  in  tumours,  predicting  the
esponse  to  EGFR-TKIs.  EGFR  status  is  then  a  favourable
s
i
wredictive  factor  in  the  case  of  sensitizing  mutations.
espite  the  positive  response  observed  in  up  to  70%  of
atients,  different  data  concluded  that  not  every  patient
eneﬁtted  from  treatment  with  TKIs,  probably  due  to
utations  in  the  downstream  effectors  of  EGFR  signalling,
ore  frequently  KRAS  gene.  Mutations  in  this  intermediate
ransduction  pathway  may  also  select  patients;  as  KRAS  acts
ownstream  of  EGFR  receptor,  its  somatic  changes  can  lead
o  a  non-response  to  EGFR-TKIs  as  response  rate  to  anti-
GFR  therapy  is  less  than  3%  in  patients  with  KRAS  mutant
umours  as  opposed  to  20%  in  NSCLC  with  wild-type  KRAS.
The  objectives  of  this  work  are  to  evaluate  EGFR  and
RAS  mutational  status,  EGFR  and  HER2  gene  copy  num-
er  and  immunohistochemical  EGFR  and  HER2  expression  in
ung  adenocarcinomas  according  to  the  patterns/subtypes
resent,  in  order  to  understand  the  value  of  pattern  recog-
ition,  supported  by  an  immunohistochemical  set  used  in
outine,  in  adenocarcinoma  diagnosis  and  anti-EGFR  therapy
ecision.
aterials and methods
aterials
 series  of  30  bronchial-pulmonary  adenocarcinomas  classi-
ed  according  with  WHO  2004  histological  classiﬁcation  and
he  new  ATS/ERS/IASLC  classiﬁcation  were  selected  from
he  archive  of  the  Pathology  Service  of  Coimbra  University
ospital.
The  patterns  present  were  registered  (namely  lep-
dic/BA,  acinar,  papillary,  micropapillary,  solid  and  muci-
ous).  Metastases  were  also  registered  by  patterns.  Clinical
ata  like  age,  gender,  smoking  habits  and  stage  were  also
egistered.
thical  standards
he  principles  of  Helsinki  Declaration  were  respected  and
he  study  was  developed  according  to  the  Faculty  of
edicine  of  the  University  of  Coimbra.
Ethical  Committee  rules  for  PhD  theses  were  followed.
mmunohistochemistry  (IHC)
epresentative  sections  of  the  adenocarcinomas  and  their
atterns  were  submitted  to  IHC  (CK7,  TTF1,  CK5/6,
D56  and  CK20)  to  validate  the  pure  condition  ofolid  pattern.  Ki67-MIB1  antibody  was  used  to  character-
ze  proliferation  index.  C-erbB-1/EGFR  and  c-erbB-2/HER2
ere  applied  to  evaluate  protein  expression  of  these
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molecules.  Endogenous  peroxidase  activity  was  quenched
using  15  min  incubation  in  3%  diluted  hydrogen  peroxide
(H2O2).  For  blocking  nonspeciﬁc  binding  with  primary  anti-
bodies  we  used  Ultra  V  Block  (Ultra  Vision  Kit;  TP-125-UB;
Lab  Vision  Corporation;  Fremont  CA;  USA).  Primary  anti-
bodies  against  CK7  (clone  OV-TL12/30;  DakoCytomation,
Glostrup,  Denmark)  at  a  dilution  of  1/50  for  30  min,  Cyto-
keratin  5,6,18  (clone  LP34;  Novocastra  Laboratories  Ltd,
Newcastle,  United  Kingdom)  at  a  dilution  of  1/100  for
60  min,  TTF1  (clone  8G7G3/1;  DakoCytomation,  Glostrup,
Denmark)  at  a  dilution  of  1/100  for  60  min,  CD56  (clone
CD564;  Novocastra  Laboratories  Ltd,  Newcastle,  United
Kingdom)  at  a  dilution  of  1:75  for  60  min,  CK20  (clone
KS20.8;  DakoCytomation,  Glostrup,  Denmark)  at  a  dilution
of  1/50  for  30  min,  Ki67  (clone  MIB-1;  DakoCytomation,
Glostrup,  Denmark)  at  a  dilution  of  1/50  for  30  min,  c-
erbB-2  (Polyclonal;  DakoCytomation,  Glostrup,  Denmark)  at
a  dilution  of  1/200  for  30  min,  and  c-erB-1  (clone  31G7;
Invitrogen,  Camarillo,  California,  USA)  at  a  dilution  of  1:20
for  30  min  were  applied  to  the  cells  and  incubated  at  room
temperature.  They  were  washed  with  phosphate-buffered
saline  (PBS)  (Ultra  Vision;  TP-125-PB;  Lab  Vision  Corpora-
tion;  Fremont  CA;  USA);  and  after  this,  for  15  min,  slides
were  incubated  with  biotin-labelled  secondary  antibody
(Ultra  Vision  Kit;  TP-125-BN;  Lab  Vision  Corporation;  Fre-
mont  CA;  USA).  Primary  antibody  binding  was  localized
in  tissues  using  peroxidase-conjugated  streptavidin  (Ultra
Vision  Kit;  TP-125-HR;  Lab  Vision  Corporation;  Fremont  CA;
USA)  and  3,3-diaminobenzidine  tetrahydrochloride  (DAB)
(RE7190-K;  Novocastra  Laboratories  Ltd,  Newcastle,  United
Kingdom)  was  used  as  chromogen,  according  to  manufac-
turer’s  instructions.  Pretreatment  was  done  with  Pronase,
10′ for  CK7,  CK5,6,18,  CK20  and  c-erbB-1,  with  MW  --micro
wave,  PH6,  20′ for  Ki67  and  c-erbB-2  and  with  MW,  EDTA,
40′ for  TTF1  and  CD56.  Haematoxylin  was  used  to  counter-
stain  the  slides  which  were  then  dehydrated  and  mounted.
In  parallel,  known  positive  and  negative  controls  were
used.
The  intensity  of  the  staining  was  graded  semi-
quantitatively  on  a  four  point  scale  (0;1+,2+,3+).  The
percentage  of  immunostained  cells  was  also  registered.  A
ﬁnal  score  was  obtained  multiplying  the  intensity  by  the  per-
centage  of  cells  with  immunohistochemical  expression  and
the  cut  off  considered  was  10%  positive  cells.
Fluorescent  in  situ  hybridization  --  FISH
The  Vysis  LSI  EGFR/CEP7  probe  assay  (Vysis; Abbott  Molecu-
lar,  USA)  was  applied  to  tumour  sections  of  4  m  thickness,
baked  overnight  at  56 ◦C,  deparafﬁnized  in  xylol,  rehy-
drated  in  100%,  70%  ethanol  and  bidistilled  water.  A  pressure
cooker  with  10  mM  citric  acid-trisodium  salt  buffer  pH  6,
for  4  min,  was  used  to  submit  slides  to  a  pre-treatment.
They  were  washed  in  2×  SSC  salts  (sodium  chloride  and
sodium  citrate)  pH  7  for  5  min  at  room  temperature.  At
15  min  slides  were  immersed  in  proteinase  K  solution  at
37 ◦C  and  then,  they  were  rinsed  in  2×  SSC  pH  7  for  5  min
at  room  temperature.  The  slides  were  then  dehydrated
in  70%,  90%  and  100%  ethanol,  and  then  air  dried.  Ten
microliters  of  probe  mixture  were  applied  on  the  target
s
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reas  and  a 22  mm  ×  22  mm  glass  coverslip  was  placed  over
robe.
After  being  sealed  with  rubber  cement  and  codenatura-
ion  at  83 ◦C  for  5  min,  coverslips  were  incubated  overnight
t  37 ◦C  in  a  humidity  chamber.  Post-hybridization  they  had
ashes  in  buffer  (50%  formamide  2×  SCC  pH  7)  at  46 ◦C  and
ere  also  washed  with  2×  SCC  pH  7.  Slides  were  air-dried
n  the  dark  and  counterstained  with  DAPI.
FISH  was  used  to  analyze  the  chromosome  7  and  EGFR
ene,  and  they  were  scored  according  to  Cappuzzo’s  (2005)
ethod.  Positive  FISH  cases  showed  high  polysomy  or
mpliﬁcation  and  the  same  procedure  was  followed  to  HER-
 probe  (HER-2/Neu  (17q12)/SE17;  Kreatech  diagnostics;
msterdam).  Positive  and  negative  FISH  cases  were  accord-
ng  to  Varella-Garcia  et  al.21
The  microscopic  analyses  were  done  in  a Nikon  Eclipse
0i  of  brilliant  ﬁeld  and  epiﬂuorescent  microscope  (LUCIA
ytogenetics  software).  Images  were  captured  and  reg-
stered  with  a  digital  camera  (Nikon  DXM  1220F),  in
onochromatic  images/layers  posterior  joint  in  one  single
mage.  This  process  was  assisted  by  Nikon  ACT-1  capture
oftware.
Overlapping  cells  were  excluded  from  analysis.  Two  sig-
als  were  counted  as  adjacent  or  fused  only  if  they  were
eparated  by  less  than  one  domain.  Two  different  individ-
als  examined  one  hundred  spindle  cells  interphase  nuclei
ith  strong  and  well-delineated  signals.
Fluorescent  signals  were  observed  and  quantiﬁed  with  a
core  previously  deﬁned  using  DAPI,  FITC,  Texas  Red  (unique
and)  and  triple  band  (DAPI,  FITC  and  Texas  Red)  ﬁlters.
CR,  sequencing  and  fragment  analysis
enomic  DNA  was  extracted  from  5  m  section  of  parafﬁn-
mbedded  tissue  after  manual  microdissection  of  all
ndependent  patterns  separation  as  supported  in  Table  1.
or  that,  the  QIAmp  DNA  Mini  Kit  (Qiagen,  IZAZA,  Germany),
as  used.  One  hundred  nanograms  (ng)  of  DNA  were  ampli-
ed  in  a 50  l reaction  solution  containing  5  l  of  10×  buffer
Roche,  Germany),  2.5  mM  MgCl2,  0.2  M  of  each  comple-
entary  primer,  200  M  deoxynucleoside  triphosphate  and
ne  unit  of  DNA  polymerase  (Roche,  Germany).  A  5  min
nitial  denaturation  at  95 ◦C  was  used  to  perform  the  ampli-
cations;  this  was  followed  by  40  cycles,  30  s at  95 ◦C,  1  min
t  60 ◦C  (for  exon  19)  or  57 ◦C  (for  exon  21),  1  min  at  72 ◦C
nd  10  min  of  ﬁnal  extension  at  72 ◦C.
The  EGFR  gene  mutations  located  at  exons  19  and  21  were
etermined  using  the  intron-based  primers  according  to  the
ublished  method.22 Mutational  analysis  of  exon  19  dele-
ion  L858R  point  mutation  of  the  EGFR  gene  was  explored,
s  described.23 The  determination  of  exon  19  deletion  was
ade  by  common  fragment  analysis  using  PCR  with  an  FAM-
abelled  primer  set,  and  the  products  were  electrophoresed
n  ABI  PRISM  3100  (Applied  Biosystems®)  and  all  eletro-
herograms  were  reanalyzed  by  visual  inspection  in  order
o  check  for  mutations.  To  evaluate  the  L858R  mutation
yCycler  (Bio-Rad)  was  also  used  and  its  products  were  then
tudied  by  direct  sequencing.
The  same  procedure  was  applied  to  KRAS  except  for
mpliﬁcation,  which  we  performed  using  a  5  min  initial
enaturation  at  95 ◦C,  followed  by  40  cycles,  30  s  at  95 ◦C,
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Table  1  Clinical  and  pathological  characteristics  of  adenocarcinomas.
Case  Gender  Age  Smoking  habits  TNM  classiﬁcation  Stage  Histologic  patterns  Metastasis
1  M  73  Non-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
2 F  71  Non-smoker  T1a  N0  Mx  IA  Lepidic/BA,  Acinar
3 M  69  Smoker  T4  N0  MX  IIIA  Lepidic/BA,  Acinar,
Papillary
4 M  75  Non-smoker  T1a  N2  Mx  IIIA  Acinar,  Solid  Acinar,  Solid
5 F  53  Non-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
6 F  62  Ex-smoker  T1a  N2  Mx  IIIA  Acinar,  Solid  Acinar,  Solid
7 F  74  Non-smoker  T1a  N0  Mx  IB  Acinar,  Solid,  Lepidic/BA
8 F  68  Non-smoker  T2a  N0  Mx  IB  Acinar,  Solid,
Micropapillary  Mucinous
9 F  50  Non-smoker  T1b  N2  Mx  IIIA  Acinar,  Solid Acinar
10 F  57  Smoker  T2a  N0  Mx  IB  Acinar,  Solid
11 M  51  Non-smoker  T1a  N1  Mx  IIA  Acinar,  Lepidic/BA  Acinar.  Solid
12 F  75  Non-smoker  T2a  N0  Mx  IB  Acinar,  Solid,
Micropapillary
13 M  85  Ex-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
Papillary
14 F  63  Smoker  T1a  N2  Mx  IB  Acinar,  Lepidic/BA
Micropapillary,  Papillary
Acinar,  Solid
15 F  55  Smoker  T1a  N0  Mx  IA  Acinar,  solid
16 F  67  Smoker  T1a  N0  Mx  IA  Lepidic/BA,  Acinar,
Micropapillary
17 M  48  Smoker  T1a  N0  Mx  IA  Acinar,  Solid,  Lepidic/BA
18 M  71  Non-smoker  T2a  N1  Mx  IIA  Acinar,  Papillay,
Micropapillary
Acinar
19 F  80  Non-smoker  T1b  N0  Mx  IA  Acinar,  Micropapillary
20 F  68  Non-smoker  T2a  N1  Mx  IIA  Acinar,  Lepidic/BA
Micropapillary
Acinar,
Micropapillary
21 M  48  Non-smoker  T2b  N1  MX  IIA  Lepidic/BA,  Acinar,  Acinar
22 F  67  Non-smoker  T2a  N0  Mx  IB  Acinar,  Mucinous
23 M  76  Ex-smoker  T1b  N0  Mx  IA  Lepidic/BA,  Acinar,
Mucinous
24 F  56  Non-smoker  T1a  N0  MX  IA  Lepidic/BA,  Acinar,
Micropapillary,  Papillary
25 M  64  Smoker  T2b  N0  Mx  IIA  Acinar,  Papillary
26 F  71  Non-smoker  T2a  N0  MX  IB  Lepidic/BA,  Acinar,  Solid
27 F  50  Smoker  T2a  N0  MX  IB  Lepidic/BA,  Solid
28 F  80  Non-smoker  T1a  N0  Mx  IA  Solid
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30 F  56  Non-smoker  T1a  N0  Mx  
 min  at  53 ◦C,  1 min  at  72 ◦C  and  a  10  min  of  ﬁnal  extension
t  72 ◦C.
The  same  procedure  was  applied  to  HER2  except  for
mpliﬁcation,  which  we  performed  using  a  1  min  initial
enaturation  at  95 ◦C;  followed  by  35  cycles,  30  s  at  95 ◦C,
 min  at  64 ◦C,  1  min  at  72 ◦C  and  10  min  of  ﬁnal  extension
t  72 ◦C.
tatistical  analyses
ASW  Statistics,  version  18,  to  do  the  statistical  analysis
f  the  information  was  applied.  To  do  the  characterization
f  the  sample  we  calculated  mean  and  standard  devi-
tion  for  quantitative  variables  and  we  determined  the
bsolute  and  relative  frequencies  for  qualitative  variables.
e  made  several  comparisons  between  nominal  variables
P
T
wIA  Lepidic/BA,  Acinar
IA  Lepidic/BA,  Acinar
gender,  smoking  habits,  mutations)  using  Chi-square  test,
isher’s  Exact  test  and  ANOVA.  Immunohistochemistry,  FISH
nd  Mutational  (PCR)  results’  concordances  were  calcu-
ated  by  kappa  coefﬁcient.  Correlation  coefﬁcient  r  was  also
alculated  (Spearman  test).  The  comparison  between  the
xistence  of  different  types  of  mutation  and  age  was  real-
zed  with  Mann--Whitney’s  test.  A  signiﬁcance  level  of  5%
p  ≤  0.05)  was  considered.
esultsatterns  and  clinical  data
able  1  shows  29  cases  of  mixed-type  adenocarcinomas
ith  registration  of  decreasing  percentage  of  the  identiﬁed
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tFigure  1  Case  21:  2+  CK20  expression;  acinar  pattern.  200×.
patterns:  28  (93.4%)  cases  with  acinar  pattern,  18  (60%)
cases  with  non-mucinous  lepidic/BA  pattern,  12  (40%)  cases
with  solid  pattern,  8  (26.7%)  cases  with  micropapillary
pattern,  6  (20%)  cases  with  papillary  pattern  and  3  (10%)
cases  with  mucinous  pattern.  Case  28  was  the  only  where
only  one  pattern  was  present  (solid  pattern).  Two  patterns
were  represented  in  16  cases  (7  cases  had  acinar  and  lep-
idic/BA  non-mucinous  patterns,  5  cases  had  acinar  and  solid
patterns,  1  case  had  acinar  and  papillary  patterns,  1  case
had  acinar  and  micropapillary  patterns,  1  case  had  acinar
and  mucinous  glandular  patterns  and  1  case  had  lepidic/BA
and  solid  patterns);  13  cases  showed  3  or  more  histological
patterns  and  of  these,  the  most  frequent  association  was
acinar,  lepidic/BA  non-mucinous  and  solid  patterns  (n  =  3),
followed  by  acinar,  lepidic/BA  non-mucinous  and  micropap-
illary  patterns  (n  =  2),  acinar,  lepidic/BA  non-mucinous
and  papillary  patterns  (n  =  2)  and  acinar,  lepidic/BA
non-mucinous,  papillary  and  micropapillary  patterns  (n  =  2).
In  this  series,  19  (63.3%)  cases  belonged  to  female  gender,
11  (36.7%)  cases  to  masculine  gender,  18  (60%)  cases  had  no
smoking  habits,  9  (30%)  cases  belonged  to  smoker  patients
and  3  (10%)  cases  to  ex-smoker  patients  (Table  1);  of  18  non-
smoking  patients  (admitting  passive  smoking),  there  were  13
females.  It  is  important  to  notice  that  histological  patterns
present  in  lymph  node  metastasis  belonged  to  acinar,  solid
and  micropapillary  morphology  (pN1/2--8  cases).
Immunohistochemistry
All  histological  types  and  patterns  identiﬁed  were  CK  5,6,18
and  CD56  negative  without  statistical  signiﬁcant  differences
(p  >  0.05).  Normal  epithelial  basal  cells  were  all  positive  for
CK5,6,18  as  internal  control;  lymph  node  metastasis  did  not
express  these  antibodies.
As  with  normal  parenchyma,  equivalent  results  were  seen
after  the  application  of  CK20  except:  in  two  cases  of  mixed-
type  adenocarcinoma,  where  acinar  and  lepidic/BA  patterns
had  a  2+  expression  (moderate  intensity)  in  50%  of  the  cells;
in  a  third  case,  the  mucinous  glandular  pattern  had  CK20
weak  expression  (1+)  in  10%  of  the  neoplastic  cells  (Fig.  1).
These  three  cases  expressed  CK7  3+  and  TTF1  3+  (Fig.  1).
Lymph  node  metastasis  had  no  CK20  expression.
c
(
t
pigure  2  Case  6:  CK7  intense  expression  (3+)  in  solid  pattern.
00×.
Mucinous  pattern  showed  lower  expression  of  CK7
han  normal  pulmonary  epithelial  cells  and  respira-
ory  cylindrical  epithelial  cells  (p  = 0.09);  acinar  pattern
p  =  0.0584),  lepidic/BA  pattern  (p  =  0.0822),  micropapil-
ary  pattern  (p  =  0.086)  and  solid  pattern  (p  =  0.0661)  had
igher  expression  of  CK7  than  mucinous  glandular  pattern
Fig.  2).
Considering  mucinous  pattern,  one  case  had  no  CK7
xpression;  CK7  expression  was  moderately  intense  (2+)  in
0%  of  the  cells  in  another  case  and  a  third  case,  had  intense
3+)  expression  in  80%  of  the  cells.
TTF1  expression  was  positive  in  normal  alveolar  septae
ells  as  expected;  it  was  negative  in  6  acinar  pattern  cases,
n  2  of  the  non-mucinous  lepidic/BA  pattern  cases,  in  1
apillary  pattern  case  and  in  2  solid  pattern  cases.  Overall
xpression,  taking  into  account  the  intensity  and  the  per-
entage  of  positive  cells,  for  TTF1  higher  expression  was
een  in  lepidic/BA  pattern  (p  =  0.002)  and  in  micropapil-
ary  pattern  (p  =  0.005),  when  compared  to  normal  alveolar
eptae.  In  mucinous  patterns,  expression  was  lower  when
ompared  to  normal  tissues  (p  =  0.0192).  There  were  no
ifferences  between  normal  tissue  and  papillary  pattern
p  =  0.315)  and  lepidic/BA  pattern  had  higher  expression
han  acinar  pattern  (p  =  0.059)  and  solid  pattern  (p  =  0.0115).
icropapillary  pattern  had  higher  expression  when  com-
ared  to  acinar  (p  =  0.0413),  solid  (p  =  0.009)  and  mucinous
p  =  0.0225)  patterns.
Adenocarcinomas  showed  higher  proliferative  index,  vali-
ated  by  Ki67  expression,  than  normal  tissues  (p  <  0.05).  Ki67
xpression  was  also  higher  in  lepidic/BA  (non-mucinous)  pat-
ern  when  compared  to  mucinous  pattern  (p  =  0.0845)  and  in
olid  compared  to  mucinous  patterns  (p  =  0.0817).  Basal  cells
n  respiratory  epithelium  expressed  Ki67  in  50%  of  cells.
We  did  not  ﬁnd  membrane  staining/expression  for  CerbB2
n  any  cases  of  the  studied  adenocarcinomas.  Cytoplas-
atic  expression  was  seen  in  all  patterns  and  in  normal
issues  adjacent  to  the  neoplasias,  with  signiﬁcant  statisti-
al  differences  between  alveolar  septae  and  acinar  patterns
p  <  0.0001),  lepidic/BA  pattern  (p  <  0.0001),  papillary  pat-
ern  (p  =  0.004),  micropapillary  pattern  (p  <  0.0001),  solid
attern  (p  =  0.0006)  and  mucinous  pattern  (p  =  0.0073).
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Higure  3  Case  7:  ErbB-2  3+  cytoplasmatic  expression;  solid
attern.  ErbB-2,  400×.
Solid  pattern  had  lower  expression  than  acinar
p  = 0.0034),  lepidic/BA  (p  =  0.004),  papillary  (p  =  0.0334)
nd  micropapillary  patterns  (p  =  0.0089)  (Figs.  3  and  4).
EGFR  membrane  immunostaining  was  revealed  in  aci-
ar  pattern  of  5  adenocarcinomas  as  moderate  (2+)  and
n  4  cases  as  intense  (3+).  We  did  not  ﬁnd  membrane
xpression  in  papillary  pattern.  In  micropapillary  pattern,
ne  case  showed  2+  membrane  expression  and  3  cases
+.  Non-mucinous  lepidic/BA  pattern  showed  2+  membrane
xpression  in  2 cases  and  3+  in  one  case.  Solid  pattern
howed  2  cases  with  2+  positivity  and  3  cases  with  3+  mem-
rane  expressions.  Mucinous  pattern  was  negative  in  all
tudied  adenocarcinomas.
Pulmonary  parenchyma  also  expressed  membranous
GFR  in  epithelial  cells  but  at  a  very  low  rate  when  com-
ared  to  adenocarcinomas  (p  =  0.0029).  Higher  expression
as  veriﬁed  in  solid  pattern  (p  =  0.097)  and  in  micropapillary
attern  (p  =  0.0457)  when  compared  to  lepidic/BA  pattern
Fig.  5).
Considering  immunohistochemical  expression  between
rimary  adenocarcinomas  patterns  and  lymph  node
igure  4  Case  8:  ErbB-2  3+  cytoplasmatic  expression;
icropapillary  pattern.  ErbB-2,  400×.
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sigure  5  Case  12:  Intense  (3+)  EGFR  expression;  acinar  pat-
ern. EGFR,  200×.
etastasis  there  was  no  statistical  signiﬁcance  for  CK7,
K20,  CK  5,6,18,  CD56,  TTF1  and  Ki67  proliferative  index.
CerbB2  was  not  expressed  as  membrane  staining  in
he  metastatic  (some  cytoplasmatic  expression  was  seen)
alignant  cells.  There  were  no  statistical  signiﬁcant  dif-
erences  between  primitive  patterns  in  adenocarcinomas
nd  respective  metastasis  (p  =  0.3711)  for  the  cytoplasmatic
tain  previously  described.
Taking  into  account  membrane  expression  of  EGFR  there
ere  no  differences  between  the  adenocarcinomas’  pat-
erns  and  the  lymph  node  metastasis  (p  =  0.108).
ER2,  EGFR  and  KRAS  mutational  status
ER2  mutations
ER2  exon  20  mutation  was  absent  in  30  cases  of  adenocar-
inomas.  All  the  patterns  were  wild-type  (WT).
GFR  mutations
GFR  exon  21  point  mutation  occurred  in  8  cases  of  the
0  adenocarcinomas  studied:  in  6  cases,  the  mutation  was
resent  in  all  the  patterns  of  the  adenocarcinoma,  in  2  cases
he  mutation  was  present  in  the  acinar  pattern  and  the  other
atterns  were  WT  (lepidic/BA  and  solid  and  lepidic/BA  pat-
erns,  respectively).
A  group  of  10  adenocarcinomas  showed  exon  19  dele-
ions:  6  with  mutations  in  all  patterns;  one  case  with
utation  in  lepidic/BA  pattern  and  acinar  pattern  WT;  the
emaining  3  cases  had  mutations  present  in  one  pattern
namely  two  cases  in  acinar  and  one  case  in  lepidic/BA  pat-
erns).
EGFR  mutations  were  present  in  42.9%  of  acinar  pattern.
GFR  mutations  were  more  frequent  in  lepidic/BA  and  acinar
atterns  (p  =  0.008).
Deletion  of  9pb  (DEL  9pb)  was  present  in  5  cases,  deletion
5pb  (DEL  15pb)  in  4  cases,  DEL  18pb  in  2  cases  and  DEL  12pb
n  one  case.
One  singular  case  showed  3  types  of  deletion,  mainly  DEL
9pb,  15pb  and  18pb  in  the  acinar  pattern  and  DEL  15pb  in
olid  and  micropapillary  patterns.
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Table  2  EGFR  exon  19  mutations  (n.p.  --  not  present  this  pattern;  n.d.  --  not  determined).
Case  Lepidic/BA  Acinar  Solid  Micropapillary  Mucinous
7  n.d.  DEL  9  pb  n.d.  n.p.  n.p.
8 n.p.  DEL  9,15,18  pb  DEL  15  pb  DEL  15  pb  n.d.
9 n.p.  DEL  9  pb  n.d.  n.p.  n.p.
12 n.p.  DEL  15  pb  DEL  15  pb  n.d.  n.p.
16 DEL  12  pb  DEL  12  pb  n.p.  DEL  12  pb  n.p.
19 n.p.  DEL  15  pb  n.p.  DEL  15  pb  n.p.
20 DEL  15  pb DEL  15  pb n.p.  n.p.  n.p.
24 DEL  9  pb DEL  9  pb n.p.  DEL  9  pb n.p.
26 DEL  18  pb n.d.  n.p.  n.p.  n.p.
30 DEL  9  pb  WT  n.p.  n.p.  n.p.
Table  3  EGFR  exon  21  mutations  (n.p.  --  not  present  in  pattern;  n.d.  --  not  determined).
Case  Lepidic/BA  Acinar  Papillary  Solid  Micropapillary  Mucinous
1  L858R  L858R  n.p.  n.p.  n.p.  n.p.
7 n.d.  L858R  n.p.  n.d.  n.p.  n.p.
14 n.d.  L858R  L858R  n.p.  n.d.  n.p.
18 n.p.  L858R  L858R  n.p.  n.d.  n.p.
23 L858R  L858R  n.p.  n.p.  n.p.  n.d.
24 L858R  L858R  n.d.  n.p.  L858R  n.p.
26 WT  L858R  n.p.  WT  n.p.  n.p.
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In  4  adenocarcinomas,  coexisting  L858R  exon  21  point
mutations  and  exon  19  deletions  were  seen.  In  two  of  these
cases  the  L858R  and  Del9pb  mutations  were  present  in
all  patterns  (acinar,  lepidic/BA  and  solid  patterns  in  one
case  and  in  acinar  pattern  in  another  case).  In  one  case,
L858R  exon  21  point  mutation  was  seen  in  acinar  pattern
and  exon  19  deletion  (DEL  18pb)  in  lepidic/BA  pattern.  In
another  case  exon  19  deletion  (DEL  9pb)  in  lepidic/BA  pat-
tern  and  L858R  exon  21  point  mutation  in  acinar  pattern
were  observed.  Tables  2  and  3  explain  the  obtained  muta-
tional  status.
The  obtained  results  showed  that  for  EGFR, exon  19
mutations  were  present  in  the  different  histological  pat-
terns  of  the  same  tumour.  In  cases  8  and  30,  lepidic/BA,
acinar,  solid  and  micropapillary  patterns  expressed  different
mutations:  in  case  8,  solid  and  micropapillary  patterns  only
expressed  DEL  15pb,  acinar  pattern  also  expressed  DEL  9pb
and  DEL  18pb  simultaneously  and  case  30  expressed  differ-
ences  between  lepidic/BA  and  acinar  patterns,  as  the  ﬁrst
one  expressed  DEL  9pb  and  the  second  one  was  WT.
In  case  26,  lepidic/BA  pattern  had  DEL  18pb  while  the
acinar  pattern  was  undetermined.
After  applying  the  Mann--Whitney  test,  patient’s  age
was  not  statistically  related  with  the  existence  of  EGFR
mutations  (neither  EGFR-Exon  19  nor  EGFR-Exon  21  muta-
tions)  with  p  =  0.156.  EGFR  mutations  were  more  frequent
in  female  patients  (p  =  0.004).
There  was  a  statistical  relationship  between  EGFR  muta-
tions  and  female  gender  (p  =  0.001)  (Chi-Square  Tests).
The  estimated  risk  obtained  Odds  ratio  for  sex  =  6.286
(95%  conﬁdence  interval  between  1.918  and  20.603)  for
females.
F
p
an.p.  n.p.  n.p.
RAS  mutations
f  the  30  adenocarcinomas  studied  5 cases  had  exon  2  point
utations,  3  of  them  of  the  type  G12  V  (Valine)  and  2  of  the
ype  G12C  (Cystein).
For  the  cases  with  KRAS  mutation,  4  had  no  EGFR  muta-
ions  with  the  exception  of  one  case  that  had  also  exon  21
GFR  mutation  and  these  mutations  were  present  in  the  two
atterns  (lepidic/BA  and  acinar)  of  this  mixed-type  adeno-
arcinoma.
In  relation  to  KRAS  exon  2 wild  type,  the  mean  age
as  66.35  years  with  a  95%  Conﬁdence  Interval  for  mean
etween  64.12  and  68.59  years,  with  a  minimum  of  50  and
 maximum  of  80  years;  for  KRAS  exon  2 mutated,  the
ean  age  was  62.60  years  with  a  95%  Conﬁdence  Interval
or  mean  between  51.16  and  74.04  years  and  with  a  min-
mum  of  48  and  a  maximum  of  85  years.  After  applying
he  Mann--Whitney  test,  no  statistical  relevance  was  found
etween  the  relation  of  KRAS-exon  2  and  the  age  of  the
ndividuals  (for  WT  and  mutated)  as  p  =  0.401  (Table  4).
KRAS  mutations  were  statistically  related  with  male  gen-
er  (p  =  0.001).  (Fisher’s  Exact  Test).
The  relationship  between  smoking  habits  and  KRAS
utations  was  statistically  relevant  (p  =  0.014)  with  higher
ncidence  in  smokers.
GFR  and  HER2  copy  number  --  FISHor  EGFR  copy  number,  12  FISH  positive  cases  (either  high
olysomy  or  ampliﬁcation)  (Figs.  6  and  7) and  18  FISH  neg-
tive  cases  were  demonstrated.  The  positive  cases  showed
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Table  4  KRAS  exon  2  mutations  (n.p.  --  not  present  in  this  pattern;  n.d.  --  not  determined).
Case  Lepidic/BA  Acinar  Papillary  Solid  Mucinous
13  n.d.  G12C  G12C  n.p.  n.p.
17 n.d.  G12V  n.p.  G12V  n.p.
21 G12V  G12V  n.p.  n.p.  n.p.
23 G12V
(EGFR
L858R)
G12V
(EGFR
L858R)
n.p.  n.p.  n.d.
29 G12C  G12C  
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Cigure  6  Case  7:  FISH  positive  for  EGFR/chromosome  7  cen-
romere.  Gene  high  polysomy;  EGFR  --  red  signal,  chromosome
-green.  1000×.
ositivity  in  all  the  patterns  present.  In  the  12  FISH  pos-
tive  cases,  3  were  EGFR  WT  and  9  had  EGFR  mutations.
n  the  other  hand,  of  the  18  FISH  negative  cases,  13  were
GFR  WT  and  5 had  EGFR  mutations  with  concordance  K
est  of  k  = 0.4595  (moderate  agreement).  These  results  were
onsistent  in  all  patterns  of  each  tumour.
When  considering  the  K  Test  for  concordance  between
ISH  results  and  each  mutational  type  (exons  21  and  19)
he  concordance  was  only  considered  as  fair  (k  =  0.2857  and = 0.2647,  respectively).
The  concordance  (K  Test)  between  mutational  status  and
GFR  immunohistochemical  expression  (positive/negative)
as  considered  fair  (k  =  0.2556).  The  concordance  (K  test)
igure  7  Case  12:  EGFR/chromosome  7.  Gene  ampliﬁcation;
ISH positive.  EGFR/chromosome  7  centromere.  EGFR  --  red
ignal,  chromosome  7-green.  1000×.
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etween  FISH  status  and  IHC  results  were  also  considered  as
air  (k  =  0.2635).
Correlation  coefﬁcient  between  immunohistochemical
GFR  expression  and  mutational  status  was  considered  not
uite  signiﬁcant  (p  =  0.0561)  with  r =  0.3525.  Correlation
oefﬁcient  between  EGFR  mutational  status  and  FISH  status
r  =  0.5303)  was  considered  very  signiﬁcant  (p =  0.0026).  No
orrelation  was  identiﬁed  between  EGFR  protein  expression
nd  FISH  status.
HER-2 FISH  positive  (mainly  by  polysomy)  cases  were
dentiﬁed  in  10  cases  corresponding  mainly  to  women  and
0  cases  were  HER-2  FISH  negative  (Table  5  concise  HER2
nd  EGFR  positive  cases).  It  was  relevant  that  FISH  nega-
ive  adenocarcinomas  had  also  FISH  negative  lymph  node
etastasis.  In  FISH  positive  adenocarcinomas,  where  lymph
odes  metastases  were  present,  they  were  HER2  FISH
egative.
iscussion
he  predictive  importance  of  making  accurate  and  more
peciﬁc  diagnosis  of  bronchial-pulmonary  carcinoma,  in
iopsies,  especially  differentiating  adenocarcinomas  from
quamous  cell  carcinoma  and  other  histological  types  was
earched  by  applying  a  panel  of  antibodies  (CK7,  TTF1,
K  5,6,18,  CK20  and  CD56)  to  establish  the  diagnosis  of
rimary  adenocarcinomas  towards  other  pulmonary  histo-
ogical  types  and  metastatic  adenocarcinomas,  following
he  proposed  classiﬁcation  for  lung  adenocarcinomas.8 IHC
as  made  to  validate  the  pure  condition  of  bronchial-
ulmonary  adenocarcinomas  mainly  to  validate  solid  pattern
nd  establish  differential  diagnosis,  as  well  as  character-
ze  proliferation  index  (Ki67-MIB1  antibody).  We  tried  also
o  identify  differences  of  expression  between  the  patterns
tudied  in  order  to  understand  and  validate  the  importance
f  differentiating  patterns.  All  morphological  patterns  were
egistered  for  each  adenocarcinoma  and  revealed  negativity
or  CK5,6,18  and  for  CD56,  excluding  squamous  and  neu-
oendocrine  differentiations,  as  shown  by  other  authors.24--26
D56  is  useful  for  excluding  neuroendocrine  differentiation,
hus  conﬁrming  that  we  are  dealing  with  pure  adenocarci-
omas,  not  combined  adenocarcinomas.
High  importance  has  been  given  to  CKs  family,  formed
y  more  than  30  polypeptides,  distributed  by  tissue  and
ifferentiation-speciﬁc  weights,  allowing  phenotyping  by
ombining  particularly  CK7,  CK20  and  epidermoid/basal
ells  high  weight  CKs  to  determine  origin  of  cell  types  or
issue.25--32
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Table  5  EGFR  and  HER2  FISH  Positive  Results.
Case  Pattern  EGFR  Estrat  HER2  Estrat
11  Lepidic/BA
Acinar
Pos
Pos
HP
HP
Neg
Neg
Dis
Dis
333 Papillary
Lepidic/BA
Acinar
Pos
Neg
Pos
HP
LP
HP
Pos
Pos
Pos
HP
HP
HP
66 Solid
Acinar
Pos
n.d.
HP
n.d.
Pos
n.d.
HP
n.d.
777 Solid
Acinar
Lepidic/BA
Pos
Pos
n.d.
HP
HP
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
8888 Acinar
Solid
Micropapillary
Mucinous
Pos
Pos
Pos
n.d.
HP
HP
HP
n.d.
Pos
Neg
Pos
n.d.
HP
BP
HP
n.d.
1111 Acinar
Lepidic/BA
Neg
n.d.
Tris
n.d.
Pos
n.d.
Amp
n.d.
121212  Solid
Acinar
Micropapillary
Pos
Pos
Pos
Amp
Amp
Amp
Neg
Neg
Neg
Tris
Tris
Tris
141414  Papillary
Acinar
Lepidic/BA
Pos
Pos
n.d.
Amp
Amp
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
1919 Micropapillary
Acinar
Pos
Pos
HP
HP
Neg
Neg
Tris
Tris
202020  Lepidic/BA
Acinar
Micropapillary
Pos
Pos
n.d.
HP
HP
n.d.
Neg
Neg
n.d.
Tris
Tris
n.d.
232323  Lepidic/BA
Acinar
Mucinous
Pos
Pos
n.d.
HP
HP
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
262626  Acinar
Solid
Lepidic/BA
Neg
Neg
n.d.
Tris
Dis
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
2727 Solid
Lepidic/BA
Pos
n.d.
HP
n.d.
Pos
n.d.
HP
n.d.
3030 Lepidic/BA
Acinar
Pos
Pos
HP
HP
Pos
Pos
HP
HP
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bEstrat. -- Estratiﬁcation for FISH results; DIS -- Disomy; LP -- Low
n.d. -- not determined.
All  morphological  registered  patterns  comprising  this
series  of  lung  adenocarcinomas  expressed  CK7  positivity,
without  differences  (p  >  0.05),  and  predominant  negativity
for  CK20,  like  other  series  published  in  the  literature.8,27,33,34
CK20  was  expressed  in  3  cases  of  primary  lung  adenocarci-
noma,  with  expression  of  CK7  and  TTF1.
Mucinous  glandular  pattern  showed  lower  expression
of  CK7  than  the  other  patterns  and  one  mucinous  pat-
tern  had  CK20  1+  expression  in  10%  of  the  cells  and
2  mixed  adenocarcinomas  showed  2+  expression  in  50%
of  the  cells  in  both  acinar  and  lepidic/BA  patterns.  At
this  point  it  is  relevant  to  make  a  comment  about  the
recently  proposed  classiﬁcation  for  lung  adenocarcinomas.8This  classiﬁcation  proposes  the  replacement  of  BA  --
bronchiolo-alveolar  pattern  carcinoma  designation  for  lep-
idic.  When  dealing  with  classical  non-mucinous  BAC,  this
histological  type  concerns  TRU  (terminal  respiratory  unit)
a
t
t
bsomy; Tris -- Trisomy; HP -- High polysomy; AMP -- Ampliﬁcation;
ells,  pool  of  adult  stem  cells  in  the  lung  where  pneu-
ocytes  type  II  and  Clara  cells  malignant  counterparts
re  recognized;  the  proposed  lepidic  pattern  seems  to
ean  going  for  a  morphologic  description  undervaluing
arcinogenesis.  Mucinous  pulmonary  adenocarcinoma  cells
xhibiting  positivity  for  intestinal  immunohistochemical
arkers,  like  CK20,  MUC2  and  COX2,  fail  to  express
TF135 and  with  bronchial  origin  may  comprise  either
ronchial  adenocarcinomas  or  intestinal  type  bronchial
denocarcinomas.  At  this  point,  the  new  proposed  lung  ade-
ocarcinoma  classiﬁcation  may  contain  a  future  relevant
mportance  by  gathering  together  all  mucinous  types  of
ronchial-pulmonary  adenocarcinomas  under  the  mucinous
denocarcinoma  umbrella,  eliminating  the  BAC  mucinous
ype  and  again,  giving  life  to  BA  pattern  referring  to
he  lepidic  non-mucinous  type.  Predictive  subtypes  will
e  described  to  clarify  origin  and  prognosis,  between
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H22  
landular  and  non-glandular  mucinous  bronchial-pulmonary
denocarcinomas.36
Also  thyroid  transcription  factor-1  (TTF-1),  tissue-
peciﬁc  transcriptional  factor,  identiﬁes  epithelial  respi-
atory  cells  involved  in  the  regulation  of  surfactant  as
neumocytes  type  II  and  Clara  cell  secretory  protein  gene
xpression  and  distinguishes  primary  lung  adenocarcinoma
rom  metastasis  of  colorectal  cancer.  With  the  exception
f  papillary  and  solid  patterns,  all  the  other  patterns  had
ntense  expression  suggesting  that  some  patterns  showing
ecreased  expression  of  TTF1  can  explain  a  small  num-
er  of  cases  developing  in  pure  CK7  positive  (bronchial)
ells.27,28 It  is  a  classical  concern  of  pathologists  to  report
 parameter  related  with  tumour  proliferation  index  and
i67-MIB1  as  a  nuclear  proliferation  associated  antigen
xpressed  in  cell  cycle  (G1,S,G2  and  M)  but  not  in  the
esting  phase,  G0,  which  provides  information  about  the
ortion  of  active  cells  in  the  cell  cycle.37,38 Ki-67  expres-
ion  by  immunohistochemistry  can  be  a  prognostic  marker
llowing  the  prediction  of  post-operative  survival  in  differ-
nt  types  of  cancer.  High  expression  of  Ki-67  (cut-off  above
0)  is  associated  with  worse  survival  in  adenocarcinomas.30
olid  pattern  expressed  higher  levels  of  Ki-67  when  com-
ared  to  micropapillary  (p  =  0.0219),  acinar  (p  =  0.0731)  and
ucinous  (p  =  0.068)  patterns  and  we  can  hypothesize  that
olid  pattern  can  have  a  worse  biological  behaviour,  either
eﬂecting  an  higher  proliferation  index  or  a  particular  differ-
ntial  origin  or  as  already  referred,  bronchial  development
hen  without  expression  of  either  TTF1  and  high  weight
olecular  cytokeratin  (CK  5,  6/CK5,  6,  18).
Membrane  expression  of  C-erbB-2  as  observed  in  breast
arcinomas  is  absent  in  lung  adenocarcinomas  and  has  been
eported  as  cytoplasmatic  since  early  90s,  in  all  morpholog-
cal  patterns.  Solid  pattern  showed  lower  expression  than
cinar,  papillary  and  micropapillary  patterns  raising  again  a
uestion  of  prediction  and  speciﬁc  genetic  pathways  worth
xploring.
In  the  literature,  there  are  numerous  references  for
mmunohistochemistry  and  genetic  studies  in  lung  adeno-
arcinomas  and  especially  under  the  old  nomenclature  of
SCLC.  The  importance  of  this  work  lies  in  the  fact  that
e  compared  IHC  expression  between  the  different  patterns
f  lung  adenocarcinomas  to  identify  differences  and  rele-
ance  between  them,  pioneering  the  searching  of  EGFR  and
RAS  mutations  together  with  EGFR  and  HER2  copy  number
lso  in  between  the  different  morphological  patterns  of  lung
denocarcinomas.
In  the  submitted  population  we  did  not  ﬁnd  correlations
etween  age  and  mutation  status,  namely  for  EGFR  and
RAS  mutations.  However  EGFR  mutations  were  more  fre-
uent  in  women  and  KRAS  mutations  in  men.  Gender  and
moking  habits  have  been  signiﬁcantly  related  with  EGFR
utations.2,3,30,39
The  commonly  reported  EGFR  mutation  rate  by  PCR
equencing  and  fragment  analyses  in  lung  adenocarcinomas
s  around  20%.40 Mutations  are  found  in  the  ﬁrst  four  exons  of
he  TK  domain  of  the  EGFR  gene.  Short-mutations,  in-frame
eletions  in  exon  19  or  point  mutations  resulting  in  a  sub-
titution  of  arginine  for  leucine  at  amino  acid  858  (L858R),
onstitute  roughly  90%  of  EGFR  mutations4,41;  45%  are  exon
9  mutations,  41%  are  exon  21  mutations  and  the  remaining
0%  are  exon  18  and  20  mutations  (approximately  4%  of  exon
f
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8  and  5%  of  exon  20)  --  ﬁrstly  described  as  more  frequent
n  females,  non-smokers,  adenocarcinomas  and  Japanese
atients.3,5,41 More  than  70%  of  NSCLC  with  EGFR  mutations
re  responsive  to  EGFR-TKIs  while  only  10%  of  tumours  with-
ut  EGFR  mutations  are  responders.4
In  our  study,  we  had  a  rate  of  EGFR  mutations  of  46%
athering  all  patterns.  Female  patients  had  a 57.9%  rate  and
ale  patients  had  a  27.3%  rate  (5  cases  in  25)  (p  =  0.001).
emale  lung  cancer  patients  have  6  times  more  risk  (Odds
atio  =  6.286)  of  having  EGFR  mutation  than  male  patients.
higematsu  and  Gazdar  deﬁned  an  EGFR  superior  mutational
ate  in  women  (49%)  than  in  male  patients  (19%).  A  reference
n  this  study  is  made  to  two  other  studies,  based  on  Japanese
ubjects,  where  over  50%  of  female  patients  with  lung  can-
er  had  higher  expression  of  EGFR  mutations.  Although  high,
ur  EGFR  mutation  rate  is  not  unique.  It  may  reﬂect  the
xhaustive  sampling  covering  all  the  patterns  present,  popu-
ation  features,  and  the  selected  population  may  have  more
dvanced  surgical  cases.  Tumour  heterogeneity  and  genetic
nstability  (leading  to  the  accumulation  of  genetic  events)
ould  explain  the  EGFR  mutation  rate  observed  as  well  as
he  presence  of  different  mutations.
We  also  tried  to  ﬁnd  the  same  relationship  for  the  iso-
ated  mutations  in  exons  19  and  21.  For  exon  19,  female
atients  had  a  rate  of  52.6%  (10  in  a  total  of  19  females)
hile  male  patients  had  a  rate  of  0%  (0  in  a  total  of  11  males),
p  =  0.000).  For  EGFR  exon  21,  we  found  no  signiﬁcant  dif-
erences  (p  =  0.835)  between  female  and  male  patients  as
emale  lung  cancer  had  a mutation  rate  of  26.3%  while  male
atients  had  a  rate  of  27.3%.  Also,  EGFR  exon  21  mutations
ere  however  more  frequent  in  women  than  in  men.
EGFR  mutations  were  described  as  more  frequent  in
ever  smokers  and  the  same  was  true  in  our  study  where
 = 0.004  (EGFR  mutation  was  present  in  60%  of  non-smokers
nd  only  in  23.1%  of  smokers).  So,  EGFR  mutations  are
till  associated  with  female  gender  and  never  smoking
tatus.  Despite  EGFR  mutations  being  more  prevalent  in  non-
mokers  we  cannot  be  sure  that  smoking  can  prevent  EGFR
utations.  These  ﬁndings  only  suggest  that  carcinogens  con-
ained  in  tobacco  smoke  are  probably  not  correlated  with
he  presence  of  EGFR  mutations  which  might  be  caused
y  another  type  of  carcinogens  than  higher  numbers’  EGFR
opies.42
Some  consider  that  FISH  EGFR  and  HER2  copy  num-
ers  may  be  used  when  DNA  quantity  is  not  sufﬁcient  for
GFR  mutation  search  as  they  showed  some  degree  of  TKI
esponses.3,19,39,42--44
HER2  has  strong  kinase  activity.3,12--14 Mutations  also
ccur  in  the  same  region  (3′ of  the  C-helix)  in  exon  20
ust  as  EGFR  in-frame  duplications/insertions,  present  in  a
ery  small  fraction  of  adenocarcinomas  of  non-smokers  and
emales,  (the  same  as  EGFR  mutations) 10,19;  the  majority
re  insertion  mutations  in  exon  20  and  the  existence  of  HER2
utations  confers  resistance  to  EGFR-TKIs  but  make  tumours
ensitive  to  HER2  target  therapies.3,10,19,45--47 In  our  study  we
id  not  ﬁnd  HER2  mutations,  indicating  lesser  importance  of
ER2  in  lung  adenocarcinomas’  carcinogenesis.
When  comparing  KRAS  exon  2  mutations  and  gender,  weound  that  male  lung  cancer  had  signiﬁcantly  more  incidence
f  mutation  than  female  cases  (p  =  0.000).  Male  patients  had
 rate  of  45.5%  (5  in  11  male  patients)  while  female  had  a
ate  of  0%  (0  in  19  female  patients).  Our  ﬁndings  are  similar
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to  Kim  et  al.  study,  who  also  realized  that  KRAS  mutations
are  signiﬁcantly  related  with  smoking  habits  (p  =  0.014)  in  a
total  rate  of  30.8%  in  smokers  while  in  non-smokers  it  was
only  5.7%.30,42
KRAS  mutations  have  been  associated  with  mucinous
differentiation,  goblet  cell,  poor  differentiation  adenocar-
cinomas  and  with  solid  patterns.48--52 However  in  our  cases
we  did  ﬁnd  this  mutation  in  acinar  and  lepidic  patterns  and
in  only  one  case  with  solid  pattern.  The  lower  number  of
poorly  differentiated  adenocarcinomas,  mucinous  and  solid
patterns  could  in  part  explain  the  lower  KRAS  mutation  rate.
EGFR  mutations  and  KRAS  mutations  have  been  described
as  mutually  exclusive  but  we  found  1  case  of  KRAS  mutation
simultaneously  with  EGFR  mutation.  So  we  conclude  that
although  EGFR  and  KRAS  mutations  are  generally  mutually
exclusive,  in  some  cases  they  can  coexist;  this  has  also  been
described  by  other  authors.11,46,53--57 The  clinical,  therapeu-
tic  and  prognostic  issues  concerning  this  coexistence  need
to  be  understood.
Although  many  studies  demonstrated  that  EGFR  muta-
tions  are  usually  related  with  an  ampliﬁcation  in  EGFR
locus,  the  relationship  between  EGFR  mutations,  gene  copy
number,  and  IHC  expression  is  still  unclear  and  without
relationship  in  our  study.40,42--44,58 We  have  demonstrated
correlation  between  mutational  EGFR  status  and  FISH  high
copy  number.  We  did  not  ﬁnd  any  correlation  with  IHC,
maybe  because  gene  ampliﬁcation  was  not  the  prevalent
event  but  gene  polysomy  reﬂecting  aneuploidy,  a  frequent
genetic  alteration  identiﬁed  in  lung  carcinomas.
Increased  copy  number  of  EGFR  was  present  in  40%
of  our  cases  which  is  comparable  to  the  36%  already
demonstrated.  In  our  study,  EGFR  mutations  had  7  times
more  risk  (Odds  Ratio  =  7.016)  of  having  EGFR  FISH  positive
(p  =  0.001)  than  EGFR  wt.  We  conclude  that  EGFR  muta-
tions  are  concordant  with  an  increased  gene  copy  number
by  FISH  (k  =  0.4595)  with  a  signiﬁcant  correlation  coefﬁcient
(r  =  0.5303;  p  =  0.0026).  This  is  relevant  because,  knowing
that  some  patients  having  high  EGFR  gene  copy  number  can
beneﬁt  from  TKI,  we  might  consider,  specially  in  cases  where
mutational  studies  are  inconclusive,  using  this  information
in  therapeutic  decisions.43,44 Concordance  of  the  EGFR  gene
copy  number  by  FISH  and  protein  expression  by  IHC  was  seen
in  7  of  12  IHC-positive  cases.44
Lepidic/BA  non-mucinous  pattern  has  been  described  as
having  mutations  of  EGFR  more  frequently.  Comparing  our
ﬁve  different  patterns  (lepidic/BA,  acinar,  papillary,  solid
and  micropapillary),  despite  not  having  statistical  signiﬁ-
cance,  EGFR  and  KRAS  mutations  were  higher  for  the  acinar
pattern  with  a  rate  of  42.9%  and  17.9%  respectively  with
no  statistical  signiﬁcance  between  them,  followed  by  the
lepidic/BA  pattern.  If  we  aggregate  lepidic/BA  and  acinar
patterns,  EGFR  mutations  are  more  frequent  in  these  two
patterns  when  compared  to  the  other  patterns  all  together
(p  =  0.008).  Recently  other  authors  showed  that  EGFR  and
KRAS  mutations  are  more  frequent  in  lung  carcinoma  with
adenocarcinoma  differentiation  based  on  p63  and  TTF1
expression,  p63  expression  being  the  most  useful  immuno-
histochemical  marker  since  they  did  not  ﬁnd  any  mutation
in  tumours  considered  p63  positive.51 In  our  work  we  went
further  correlating  the  mutational  status  also  with  the  his-
tological  patterns  present.  Generally,  when  a  mutation  is
present  it  is  present  in  all  the  histological  patterns  of  the
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ame  adenocarcinoma  (Tables  2--4).  Biopsies,  representing
nly  a  small  portion  of  a  tumour,  can  be  used  to  determine
GFR  and  KRAS  mutational  status.
The  conclusions  referred  to  above  are  predictive  and
gain  raise  the  controversies  explored  in  the  proposed  lung
denocarcinomas  classiﬁcation:  a  small  biopsy  with  a  carci-
oma  CK7  positive  and  TTF1  positive  is  an  adenocarcinoma
CK  5,6,18  negative)  and  has  to  be  submitted  to  KRAS  muta-
ion  search  in  a  male  patient,  when  acinar,  solid  pattern  and
epidic/BA  (non-mucinous  type)  pattern  are  present  and  also
o  EGFR  mutational  search  for  TKIs  prescription  decision.
Also  to  summarize,  some  adenocarcinomas  show  CK20
ositivity  in  mucinous  patterns/subtypes  and  solid  patterns
how  lower  expression  of  nuclear  TTF1  and  higher  expression
f  Ki67,  reﬂecting  probably  a  particular  cell  origin  and  more
ggressive  biological  behaviour  and  have  to  be  reported  as
ung  adenocarcinomas,  avoiding  poorly  differentiated  carci-
oma  designation.
After  this  study,  it  seems  that  EGFR  and  KRAS  mutational
tatus  can  be  determined  in  biopsies  representing  bronchial
ulmonary  carcinomas  because  when  a  mutation  is  present  it
s  generally  present  in  all  the  histological  patterns,  needing
urther  equivalent  studies  supported  by  a practical  immuno-
istochemical  panel.
onclusions
he  differences  identiﬁed  between  the  adenocarcinoma
atterns  reinforce  the  necessity  to  carefully  identify
he  patterns  present  with  implications  for  diagnosis
nd  pathogenic  understanding.  Correlation  was  found  in
etween  EGFR  FISH  results  and  mutational  status.  There
re  adenocarcinomas  harbouring  different  EGFR  mutations
n  different  patterns.  In  general,  EGFR  mutation  is  present  in
ll  the  patterns  of  the  same  adenocarcinoma  reinforcing  the
ossibility  of  mutational  status  determination  in  biopsies.
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